Hundreds of residents have complained about pancreas problems after taking semaglutide or other recently approved GLP-1s, with many cases documented in 2025 alone

Try the BMI Calculator Table of contents The FDA-approved indication: what the label actually says How oral semaglutide works differently from injectable forms The dosing ceiling problem: why 14 mg daily doesn't equal 2.4 mg weekly Clinical trial data: A1C reduction and weight outcomes What most articles get wrong about Rybelsus and weight loss Off-label use patterns and the insurance coverage gap Cardiovascular outcomes: the data we have vs the data we're waiting for When providers choose Rybelsus over injectable GLP-1s The absorption challenge: why timing and food matter more than with injections Rybelsus vs Ozempic vs Wegovy: same molecule, different approvals FormBlends clinical pattern: who succeeds on oral semaglutide FAQ Sources The FDA-approved indication: what the label actually says Rybelsus received FDA approval on September 20, 2019, with a single indication: "adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus." The label explicitly states three things Rybelsus is NOT approved for: Treatment of type 1 diabetes Treatment of diabetic ketoacidosis Use in patients with a history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) Notably absent from the approval: any mention of weight loss, obesity, or weight management

Aroda VR, Rosenstock J, Terauchi Y, Altuntas Y, Lalic NM, Morales Villegas EC, et al
CROI 2024 (Conference on Retroviruses and Opportunistic Infections), March 3-6, 2024, Denver
Funding was reported in 22.0% of the studies
Because Jardiance and diuretics can increase urination, taking these medications together may lead to low fluid levels in the body, leading to dehydration and potential kidney problems